scholarly journals Serum Concentration of Fluoride in Patients with Alcoholic Liver Cirrhosis from the Lublin Region in Eastern Poland

2021 ◽  
Vol 18 (3) ◽  
pp. 1115
Author(s):  
Andrzej Prystupa ◽  
Jarosław Sak ◽  
Paweł Kiciński ◽  
Agnieszka Stenzel-Bembenek ◽  
Anna Błażewicz
Keyword(s):  
Liver Cirrhosis ◽  
Liver Function ◽  
Serum Concentration ◽  
Total Bilirubin ◽  
Alcoholic Liver Cirrhosis ◽  
Serum Concentrations ◽  
Bilirubin Concentration ◽  
Severity Of Disease ◽  
Total Bilirubin Concentration ◽  
The Relationship

In view of previous reports, it is important to determine the relationship between liver function and the level of fluoride in the serum. The aim of this study was to investigate serum concentrations of fluoride in 72 patients with alcoholic liver cirrhosis, living in the region of Lublin (Eastern Poland) divided based on the severity of disease according to the Child-Turcotte-Pugh criteria. Higher plasma fluoride concentrations were associated with changes in liver related parameters. In all groups of analyzed patients with different stages of alcoholic liver cirrhosis, elevated levels of plasma fluoride and increased activities of both alanine aminotransferase (ALT) and total bilirubin concentration were shown.

Hyperbilirubinemia in Preterm Infants and Neurodevelopmental Outcome at 2 Years of Age: Results of a National Collaborative Survey

PEDIATRICS ◽  
1989 ◽  
Vol 83 (6) ◽  
pp. 915-920
Author(s):  
Margot van de Bor ◽  
Thea M. van Zeben-van der Aa ◽  
S. Pauline Verloove-Vanhorick ◽  
Ronald Brand ◽  
Jan H. Ruys
Keyword(s):  
Birth Weight ◽  
Gestational Age ◽  
Total Bilirubin ◽  
Neurodevelopmental Outcome ◽  
Serum Total Bilirubin ◽  
Bilirubin Concentration ◽  
Total Bilirubin Concentration ◽  
Consistent Increase ◽  
The Relationship

As part of a prospective national survey of preterm and small for gestational age infants in the Netherlands, the relationship between maximal serum total bilirubin concentration in the neonatal period and neurodevelopmental outcome at the corrected age of 2 years was studied. Initially, 1,338 infants with a gestational age of less than 32 completed weeks and/or a birth weight of less than 1,500 g were enrolled in the study; 146 were subsequently excluded because of congenital malformations and 361 died during the study period. At the corrected age of 2 years, 831 children were available for follow-up. Children with minor and major handicaps had significantly greater maximal serum total bilirubin concentrations than children with a normal neurodevelopmental outcome (P = .02). A consistent increase in prevalence of handicaps was found for each 50-µmol/L (2.9 mg/dL) increase of maximal serum total bilirubin concentration. The handicaps consisted mainly of cerebral palsy. Logistic regression analysis involving seven suspected confounding factors (gestational age, birth weight, seizures, intracranial hemorrhage, respiratory distress syndrome, ventriculomegaly, and bronchopulmonary dysplasia) revealed that the odds ratio was 1.3. This indicates that, on a multiplicative scale, the risk of a handicap increased by 30% for each 50-µmol/L (2.9 mg/dL) increase of maximal serum total bilirubin concentration (P = .02). Further analysis treated bilirubin as a categorized exposure. A striking systematic increase was found, suggesting a causal relationship between maximal serum total bilirubin concentration and neurodevelopmental outcome.

Hyperbilirubinemia in Low Birth Weight Infants and Outcome at 5 Years of Age

PEDIATRICS ◽  
1992 ◽  
Vol 89 (3) ◽  
pp. 359-364
Author(s):  
Margot van de Bor ◽  
Martina Ens-Dokkum ◽  
Anneke M. Schreuder ◽  
Sylvia Veen ◽  
Ronald Brand ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Intracranial Hemorrhage ◽  
Gestational Age ◽  
Odds Ratio ◽  
Total Bilirubin ◽  
Neonatal Period ◽  
Serum Total Bilirubin ◽  
Bilirubin Concentration ◽  
Total Bilirubin Concentration ◽  
The Relationship

The collaborative national survey on morbidity and mortality in preterm and small for gestational age infants in the Netherlands enrolled initially 1338 infants born in 1983. The relationship between maximal serum total bilirubin concentration in the neonatal period and neurodevelopmental outcome in the survivors of this cohort was studied. This relationship at the corrected age of 2 years was previously reported. A dose-response relationship between maximal serum total bilirubin concentration and risk of adverse outcome was observed in the 831 surviving children. The present study reassessed the relationship at the age of 5 years in 814 children. There was no significant difference in mean maximal serum total bilirubin concentration between the children with and without a handicap. This was confirmed by logistic regression analysis. After correction for seven suspected confounding factors (gestational age, birth weight, intracranial hemorrhage, ventriculomegaly, seizures, bronchopulmonary dysplasia, and socioeconomic status) the estimated odds ratio was 1.2 (confidence interval 0.89, 1.43) per 50 µmol/l increase of total bilirubin. However, in this analysis an interaction between bilirubin and intracranial hemorrhage was observed. Therefore, the cohort was divided into two groups according to the absence or presence of an intracranial hemorrhage. Logistic regression analysis including four suspected confounding factors (gestational age, ventriculomegaly. seizures, and socioeconomic status) was then again applied. In children who had suffered from an intracranial hemorrhage in the neonatal period the estimated odds ratio was 1.84 (confidence interval 1.08, 3.15) per 50 µmol/l increase of bilirubin. Similar results were obtained treating bilirubin as a categorized exposure. The odds ratio in children without a hemorrhage was 1.05 (confidence interval 0.80, 1.38), probably because of the small number of surviving handicapped children.

scholarly journals Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function

2000 ◽  
Vol 44 (4) ◽  
pp. 821-826 ◽  
Author(s):  
Laurence Veronese ◽  
Jacques Rautaureau ◽  
Brian M. Sadler ◽  
Catherine Gillotin ◽  
Jean-Pierre Petite ◽  
...  
Keyword(s):  
Liver Disease ◽  
Healthy Volunteers ◽  
Total Bilirubin ◽  
Laboratory Data ◽  
Hepatic Insufficiency ◽  
Pharmacokinetic Parameters ◽  
Control Group ◽  
Bilirubin Concentration ◽  
Total Bilirubin Concentration ◽  
Severe Cirrhosis

ABSTRACT Amprenavir (141W94) is extensively metabolized by P450 cytochromes, specifically, CYP3A4. Because hepatic insufficiency reduces P450-mediated metabolism, the concentrations in plasma of drugs metabolized through this pathway are often increased in subjects with liver disease. Following administration of a single, oral dose of 600 mg of amprenavir, pharmacokinetic parameters were determined for 10 subjects with severe cirrhosis, 10 subjects with moderate cirrhosis, and 10 healthy volunteers. Model-independent methods for determining the area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC0–∞) showed an increase in amprenavir AUC0–∞ of 2.5-fold in the group with moderate cirrhosis and 4.5-fold in the group with severe cirrhosis compared with that in the control group of healthy volunteers (P < 0.05). AUC0–∞ was linearly related to the severity of liver disease, as assessed by the Child-Pugh score. Of the laboratory data used to calculate the Child-Pugh score, only the mean total bilirubin concentration showed a significant relationship with AUC0–∞. The relationship between the total bilirubin concentration and the AUC0–∞ of amprenavir was well characterized by a simple E max model, suggesting that the total bilirubin concentration may be a useful parameter for predicting the amprenavir AUC in subjects with hepatic insufficiency. Finally, the sera of cirrhotic subjects showed significant decreases in the levels of α1-acid glycoprotein, the primary plasma binding protein for amprenavir. On the basis of the results of this study, for an exposure equivalent to a clinical dose of 1,200 mg twice daily in subjects without cirrhosis, subjects with Child-Pugh scores of 5 to 8 should receive a twice-daily 450-mg dose of amprenavir, and subjects with Child-Pugh scores of 9 to 15 should receive a twice-daily 300-mg dose of amprenavir.

scholarly journals Transplantation of Autologous Mesenchymal Stem Cells for End-Stage Liver Cirrhosis: A Meta-Analysis Based on Seven Controlled Trials

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Xiang-Rui Ma ◽  
Ya-Ling Tang ◽  
Ming Xuan ◽  
Zheng Chang ◽  
Xiao-Yi Wang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Liver Cirrhosis ◽  
Liver Function ◽  
Serum Albumin ◽  
Total Bilirubin ◽  
Meta Analysis ◽  
Meld Score ◽  
End Stage

Background. The bone marrow-derived mesenchymal stem cells (BM-MSCs) have demonstrated great potential as regenerative medicine in different therapeutic applications. This study aims to pool previous controlled clinical trials to make an update assessment of the effectiveness of BM-MSC transplantation on end-stage liver cirrhosis.Methods. Relevant studies published between January 1990 and June 2014 were searched among Pubmed, Embase, and ClinicalTrial.gov. A meta-analysis was performed to assess the effect of BM-MSCs on liver function indicators, including Models of End-Stage Liver Disease (MELD) score, serum albumin (g/L), total bilirubin (mg/dl), Prothrombin concentration (%), and alanine aminotransferase (ALT) (U/L).Results. BM-MSCs therapy could significantly improve liver function in patients with end-stage liver cirrhosis, in terms of MELD score, serum albumin, total bilirubin, and prothrombin concentration, at least during the half year after transplantation.Conclusions. Due to BM-MSCs’ immunomodulatory functions and the potential to differentiate into hepatocytes, they are a promising therapeutic agent to liver cirrhosis. Considering currently available evidence, this therapy is relatively safe and effective in improving liver function. However, how different variables should be controlled to optimize the therapeutic effect is still not clear. Thus, future mechanism studies and clinical trials are required for this optimization.

Oral Testosterone Load Related to Liver Function in Men with Alcoholic Liver Cirrhosis

1983 ◽  
Vol 18 (3) ◽  
pp. 391-396 ◽  
Author(s):  
C. Gluud ◽  
M. Bahnsen ◽  
P. Bennett ◽  
O. Dietrichson ◽  
J. H. Henriksen ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Liver Function ◽  
Alcoholic Liver Cirrhosis

Serum Total Bilirubin Concentration Is Inversely Correlated with Framingham Risk Score in Koreans

2012 ◽  
Vol 43 (4) ◽  
pp. 288-293 ◽  
Author(s):  
Kwang-Min Kim ◽  
Bom-Taeck Kim ◽  
Sat-Byul Park ◽  
Doo-Yeoun Cho ◽  
Sang Hyeon Je ◽  
...  
Keyword(s):  
Risk Score ◽  
Framingham Risk Score ◽  
Total Bilirubin ◽  
Serum Total Bilirubin ◽  
Bilirubin Concentration ◽  
Framingham Risk ◽  
Total Bilirubin Concentration
Sign in / Sign up

Export Citation Format

Share Document